Reuters logo
a month ago
BRIEF-Pluristem advances its limb ischemia study, targeting initiation at 40 active sites by the year end
July 10, 2017 / 11:22 AM / a month ago

BRIEF-Pluristem advances its limb ischemia study, targeting initiation at 40 active sites by the year end

July 10 (Reuters) - Pluristem Therapeutics Inc

* Pluristem advances its multinational phase III critical limb ischemia study, targeting initiation at 40 active sites by the end of 2017

* ‍Austria's regulatory health agency clears CLI study and joins U.S., U.K., and Germany in conducting 250-patient phase III trial​

* ‍Phase III CLI trial has received an $8 million grant from European Union's horizon 2020 program​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below